Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Pediatric rheumatic disease

Treating lupus nephritis in children—is there a gold standard?

New consensus treatment plans state that the combination of glucocorticoids and immunosuppression is treatment of choice for newly diagnosed pediatric patients with proliferative lupus nephritis. However, variations exist in the steroid protocol and in the type of immunosuppressant used, indicating that a gold-standard treatment protocol is yet to be achieved.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Mina, R. et al. Consensus treatment plans for induction therapy of newly-diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res. (Hoboken) http://dx.doi.org/10.1002/acr.21558.

  2. Livingston, B., Bonner, A. & Pope, J. Differences in clinical manifestations between childhood-onset lupus and adult-onset lupus: a meta-analysis. Lupus 20, 1345–1355 (2011).

    Article  CAS  Google Scholar 

  3. Crow, Y. J. Lupus: How much “complexity” is really (just) genetic heterogeneity? Arthritis Rheum. 63, 3661–3664 (2011).

    Article  Google Scholar 

  4. Appel, G. B. et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 20, 1103–1112 (2009).

    Article  CAS  Google Scholar 

  5. Lau, K. K., Ault, B. H., Jones, D. P. & Butani, L. Induction therapy for pediatric focal proliferative lupus nephritis: cyclophosphamide versus mycophenolate mofetil. J. Pediatr. Health Care 22, 282–288 (2008).

    Article  Google Scholar 

  6. Hagelberg, S. et al. Long-term follow-up of childhood lupus nephritis. J. Rheumatol. 29, 2635–2642 (2002).

    PubMed  Google Scholar 

  7. Pereira, T. et al. Three decades of progress in treating childhood-onset lupus nephritis. Clin. J. Am. Soc. Nephrol. 6, 2192–2199 (2011).

    Article  CAS  Google Scholar 

  8. Guiducci, C. et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 465, 937–941 (2010).

    Article  CAS  Google Scholar 

  9. Zahr, N. et al. Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. Arthritis Rheum. 62, 2047–2054 (2010).

    CAS  PubMed  Google Scholar 

  10. Díaz-Lagares, C. et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts. Autoimmun. Rev. http://dx.doi.org/10.1016/j.autorev.2011.10.009.

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cimaz, R. Treating lupus nephritis in children—is there a gold standard?. Nat Rev Rheumatol 8, 192–193 (2012). https://doi.org/10.1038/nrrheum.2012.19

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2012.19

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing